187 related articles for article (PubMed ID: 24205241)
21. Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma.
Cazes A; Louis-Brennetot C; Mazot P; Dingli F; Lombard B; Boeva V; Daveau R; Cappo J; Combaret V; Schleiermacher G; Jouannet S; Ferrand S; Pierron G; Barillot E; Loew D; Vigny M; Delattre O; Janoueix-Lerosey I
Cancer Res; 2013 Jan; 73(1):195-204. PubMed ID: 23139213
[TBL] [Abstract][Full Text] [Related]
22. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours.
Carén H; Abel F; Kogner P; Martinsson T
Biochem J; 2008 Dec; 416(2):153-9. PubMed ID: 18990089
[TBL] [Abstract][Full Text] [Related]
23. NKAIN2 functions as a novel tumor suppressor in prostate cancer.
Mao X; Luo F; Boyd LK; Zhou B; Zhang Y; Stankiewicz E; Marzec J; Vasiljevic N; Yu Y; Feng N; Xu J; Lorincz A; Jiang Y; Chelala C; Ren G; Berney DM; Zhao SC; Lu YJ
Oncotarget; 2016 Sep; 7(39):63793-63803. PubMed ID: 27588475
[TBL] [Abstract][Full Text] [Related]
24. Accumulation of potential driver genes with genomic alterations predicts survival of high-risk neuroblastoma patients.
Suo C; Deng W; Vu TN; Li M; Shi L; Pawitan Y
Biol Direct; 2018 Jul; 13(1):14. PubMed ID: 30012197
[TBL] [Abstract][Full Text] [Related]
25. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma.
Bourdeaut F; Trochet D; Janoueix-Lerosey I; Ribeiro A; Deville A; Coz C; Michiels JF; Lyonnet S; Amiel J; Delattre O
Cancer Lett; 2005 Oct; 228(1-2):51-8. PubMed ID: 15949893
[TBL] [Abstract][Full Text] [Related]
26. PPM1D is a potential target for 17q gain in neuroblastoma.
Saito-Ohara F; Imoto I; Inoue J; Hosoi H; Nakagawara A; Sugimoto T; Inazawa J
Cancer Res; 2003 Apr; 63(8):1876-83. PubMed ID: 12702577
[TBL] [Abstract][Full Text] [Related]
27. Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization.
Bedrnicek J; Vicha A; Jarosova M; Holzerova M; Cinatl J; Michaelis M; Cinatl J; Eckschlager T
Neoplasma; 2005; 52(5):415-9. PubMed ID: 16151587
[TBL] [Abstract][Full Text] [Related]
28. PHOX2B analysis in non-syndromic neuroblastoma cases shows novel mutations and genotype-phenotype associations.
McConville C; Reid S; Baskcomb L; Douglas J; Rahman N
Am J Med Genet A; 2006 Jun; 140(12):1297-301. PubMed ID: 16691592
[TBL] [Abstract][Full Text] [Related]
29. ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.
Borenäs M; Umapathy G; Lai WY; Lind DE; Witek B; Guan J; Mendoza-Garcia P; Masudi T; Claeys A; Chuang TP; El Wakil A; Arefin B; Fransson S; Koster J; Johansson M; Gaarder J; Van den Eynden J; Hallberg B; Palmer RH
EMBO J; 2021 Feb; 40(3):e105784. PubMed ID: 33411331
[TBL] [Abstract][Full Text] [Related]
30. PHOX2A and PHOX2B genes are highly co-expressed in human neuroblastoma.
Longo L; Borghini S; Schena F; Parodi S; Albino D; Bachetti T; Da Prato L; Truini M; Gambini C; Tonini GP; Ceccherini I; Perri P
Int J Oncol; 2008 Nov; 33(5):985-91. PubMed ID: 18949361
[TBL] [Abstract][Full Text] [Related]
31. miR-204 mediates post-transcriptional down-regulation of PHOX2B gene expression in neuroblastoma cells.
Bachetti T; Di Zanni E; Ravazzolo R; Ceccherini I
Biochim Biophys Acta; 2015 Aug; 1849(8):1057-65. PubMed ID: 26145533
[TBL] [Abstract][Full Text] [Related]
32. [Abnormality of anaplastic lymphoma kinase gene and its expression in pediatric neuroblastoma].
Chen S; Zhou C; Ma X; Gong L
Zhonghua Bing Li Xue Za Zhi; 2014 Aug; 43(8):541-5. PubMed ID: 25346125
[TBL] [Abstract][Full Text] [Related]
33. The use of ultra-dense array CGH analysis for the discovery of micro-copy number alterations and gene fusions in the cancer genome.
Przybytkowski E; Ferrario C; Basik M
BMC Med Genomics; 2011 Jan; 4():16. PubMed ID: 21272361
[TBL] [Abstract][Full Text] [Related]
34. Germline gain-of-function mutations of ALK disrupt central nervous system development.
de Pontual L; Kettaneh D; Gordon CT; Oufadem M; Boddaert N; Lees M; Balu L; Lachassinne E; Petros A; Mollet J; Wilson LC; Munnich A; Brugière L; Delattre O; Vekemans M; Etchevers H; Lyonnet S; Janoueix-Lerosey I; Amiel J
Hum Mutat; 2011 Mar; 32(3):272-6. PubMed ID: 21972109
[TBL] [Abstract][Full Text] [Related]
35. Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma.
Andolfo I; Lasorsa VA; Manna F; Rosato BE; Formicola D; Iolascon A; Capasso M
J Cell Mol Med; 2020 Jun; 24(11):6459-6471. PubMed ID: 32336043
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma.
Raabe EH; Laudenslager M; Winter C; Wasserman N; Cole K; LaQuaglia M; Maris DJ; Mosse YP; Maris JM
Oncogene; 2008 Jan; 27(4):469-76. PubMed ID: 17637745
[TBL] [Abstract][Full Text] [Related]
37. ALK Gene Copy Number Gain and Immunohistochemical Expression Status Using Three Antibodies in Neuroblastoma.
Kim EK; Kim S
Pediatr Dev Pathol; 2017; 20(2):133-141. PubMed ID: 28326957
[TBL] [Abstract][Full Text] [Related]
38. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
39. Constitutional 3p26.3 terminal microdeletion in an adolescent with neuroblastoma.
Pezzolo A; Sementa AR; Lerone M; Morini M; Ognibene M; Defferrari R; Mazzocco K; Conte M; Gigliotti AR; Garaventa A; Pistoia V; Varesio L
Cancer Biol Ther; 2017 May; 18(5):285-289. PubMed ID: 28402723
[TBL] [Abstract][Full Text] [Related]
40. Molecular pathogenesis of peripheral neuroblastic tumors.
Janoueix-Lerosey I; Schleiermacher G; Delattre O
Oncogene; 2010 Mar; 29(11):1566-79. PubMed ID: 20101209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
